MGIM
CRSP icon

M&G Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

M&G Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,224
Closed -$361 – 547
2021
Q3 		$361 Sell
3,224
-2,240
-41% -$281K ﹤0.01% 694
2021
Q2 		$885 Buy
+5,464
New +$665K ﹤0.01% 637

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

M&G Investment Management's CRSP Position: Q4 2021 in Review

M&G Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 3,224 shares — an estimated $361 sold.

M&G Investment Management first reported a position in CRSP in Q2 2021 and held it in 2 quarters. The position peaked at $885 in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • M&G Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • M&G Investment Management sold 3,224 CRISPR Therapeutics shares in Q4 2021, an estimated $361.
  • M&G Investment Management first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 2 quarters.
  • M&G Investment Management's CRISPR Therapeutics position peaked at $885 in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.